全文获取类型
收费全文 | 128537篇 |
免费 | 9482篇 |
国内免费 | 208篇 |
专业分类
耳鼻咽喉 | 1193篇 |
儿科学 | 3581篇 |
妇产科学 | 2727篇 |
基础医学 | 20266篇 |
口腔科学 | 3381篇 |
临床医学 | 10911篇 |
内科学 | 25531篇 |
皮肤病学 | 2238篇 |
神经病学 | 12470篇 |
特种医学 | 5288篇 |
外国民族医学 | 16篇 |
外科学 | 16088篇 |
综合类 | 537篇 |
一般理论 | 108篇 |
预防医学 | 14683篇 |
眼科学 | 2012篇 |
药学 | 7828篇 |
中国医学 | 238篇 |
肿瘤学 | 9131篇 |
出版年
2023年 | 513篇 |
2022年 | 422篇 |
2021年 | 1578篇 |
2020年 | 1457篇 |
2019年 | 2122篇 |
2018年 | 2664篇 |
2017年 | 2285篇 |
2016年 | 2411篇 |
2015年 | 2734篇 |
2014年 | 3737篇 |
2013年 | 4940篇 |
2012年 | 7643篇 |
2011年 | 7683篇 |
2010年 | 3950篇 |
2009年 | 4183篇 |
2008年 | 6815篇 |
2007年 | 7009篇 |
2006年 | 6784篇 |
2005年 | 6421篇 |
2004年 | 5454篇 |
2003年 | 5173篇 |
2002年 | 4723篇 |
2001年 | 4558篇 |
2000年 | 4563篇 |
1999年 | 4030篇 |
1998年 | 1526篇 |
1997年 | 1240篇 |
1996年 | 1314篇 |
1995年 | 1182篇 |
1994年 | 1095篇 |
1993年 | 995篇 |
1992年 | 2773篇 |
1991年 | 2509篇 |
1990年 | 2396篇 |
1989年 | 2226篇 |
1988年 | 2035篇 |
1987年 | 1792篇 |
1986年 | 1707篇 |
1985年 | 1633篇 |
1984年 | 1164篇 |
1983年 | 1004篇 |
1982年 | 537篇 |
1981年 | 473篇 |
1980年 | 408篇 |
1979年 | 885篇 |
1978年 | 532篇 |
1977年 | 439篇 |
1974年 | 442篇 |
1973年 | 431篇 |
1972年 | 384篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
1.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
2.
3.
4.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
5.
van der Meulen Merel Verstegen Marco J. T. Lobatto Daniel J. Kleijwegt Maarten C. Pereira Alberto M. Biermasz Nienke R. van Furth Wouter R. Zamanipoor Najafabadi Amir H. 《Pituitary》2022,25(2):308-320
Pituitary - Endoscopic transsphenoidal surgery causes nasal morbidity and negatively affects health-related quality of life (HRQoL). Knowledge on actionable symptoms that could improve... 相似文献
6.
Mandy van Gulijk Bob Belderbos Daphne Dumoulin Robin Cornelissen Koen Bezemer Larissa Klaase Floris Dammeijer Joachim Aerts 《International journal of cancer. Journal international du cancer》2023,152(7):1438-1443
Immunotherapy with anti-PD1/PD-L1 is effective in only a subgroup of patients with malignant pleural mesothelioma (MPM). We investigated the efficacy of a combination of anti-PD1/PD-L1 and dendritic cell (DC) therapy to optimally induce effective anti-tumor immunity in MPM in both humans and mice. Data of nine MPM patients treated with DC therapy and sequential anti-PD1 treatment were collected and analyzed for progression-free survival (PFS) and overall survival (OS). Survival and T-cell responses were monitored in AC29 mesothelioma-bearing mice treated concurrently with the combination therapy; additionally, the role of the tumor-draining lymph node (TDLN) was investigated. The combination therapy resulted in a median OS and PFS of 17.7 and 8.0 months, respectively. Grade 3 to 4 treatment-related adverse events had not been reported. Survival of the mesothelioma-bearing mice treated with the combination therapy was longer than that of untreated mice, and coincided with improved T-cell activation in peripheral blood and less T-cell exhaustion in end stage tumors. Comparable results were obtained when solely the TDLN was targeted. We concluded that this combination therapy is safe and shows promising OS and PFS. The murine data support that PD-L1 treatment may reinvigorate the T-cell responses induced by DC therapy, which may primarily be the result of TDLN targeting. 相似文献
7.
8.
Rohde Sofie Muslem Rahatullah Kaya Emrah Dalinghaus Michel van Waning Jaap I. Majoor-Krakauer Danielle Towbin Jeffery Caliskan Kadir 《Heart failure reviews》2022,27(1):15-28
Heart Failure Reviews - Noncompaction cardiomyopathy (NCCM) is a disease characterized by hypertrabeculation, commonly hypothesized due to an arrest in compaction during fetal development. In 2006,... 相似文献
9.
10.
Two-year results after combined phacoemulsification and iris-fixated phakic intraocular lens removal
Gaurisankar Zoraida Solaiga van Rijn Gwyneth A. Cheng Yanny Y. Y. Luyten Gregorius P. M. Beenakker Jan-Willem M. 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(4):1367-1375
Graefe's Archive for Clinical and Experimental Ophthalmology - To describe and present results after a technique for cataract surgery combined with explantation of an iris-fixated phakic... 相似文献